In a recent development, a Delaware federal judge issued a sealed order, negating the dismissal of an antitrust lawsuit filed by drugmakers Sage Chemical Inc. and TruPharma. The suit accuses rival firm Supernus Pharmaceuticals, along with others, of deliberately suppressing generic versions of the Parkinson’s treatment Apokyn.
The lawsuit by Sage Chemical and TruPharma stands as a significant legal battle in the pharmaceutical industry. Claims made by these two drugmakers shine light on the crucial matter of potential antitrust violations in the sector, particularly around the production and sale of treatment aids for neurological conditions such as Parkinson’s Disease.
The involved parties – Sage Chemical Inc., TruPharma, Supernus Pharmaceuticals – are yet to broadcast any public statements following the judge’s refusal to dismiss the case. How these pharmaceutical firms and the wider industry react to and handle such accusations will have substantial implications for the future course of generic drug production and distribution.
Further details around the case and the judge’s statement are still undisclosed as the order remains sealed. We will provide updates as more information becomes available.
To review the preliminary court document on this lawsuit, please visit Law360.